Tatva Chintan Pharma Chem Q3 FY26 Recovery Triggers ICICI Securities’ Positive View and Upside Target

Tatva Chintan Pharma Chem Ltd is back on the radar of market participants after a sharp operational recovery, with ICICI Securities reiterating a positive view on the stock. The brokerage has a target price of Rs 1,955 per share, implying about 70.4% upside from the prevailing level of Rs 1,147.50, supported by stronger earnings and forward guidance.

The small-cap speciality chemicals company has also drawn interest from investors on D-Street, as the share price advanced 5.17% over the last five trading sessions. The recovery in profitability during Q3 FY26, along with management’s commentary on future growth, is shaping expectations for steady improvement in both volumes and margins over the coming years.

The December 2025 quarter showed a broad-based turnaround in the company’s financials compared to the previous year. Net profit for Q3FY26 surged to Rs 15.98 crore from Rs 1.17 crore in Q3FY25, a rise of 1472.02%. Earnings per share moved up from Rs 0.50 in the year-ago period to Rs 6.84 in the latest quarter.

Revenue and operating performance also improved meaningfully for Tatva Chintan Pharma Chem in Q3FY26. Net sales climbed 64.99% year-on-year, increasing from Rs 84.00 crore in the quarter ended December 2024 to Rs 138.59 crore in the quarter ended December 2025. EBITDA grew from Rs 5.68 crore to Rs 28.36 crore, reflecting an increase of 399.3%.

For finance readers tracking quarterly trends in Tatva Chintan Pharma Chem, the key reported numbers for the December quarters are summarised below.

Metric	Q3FY25 (Dec 2024)	Q3FY26 (Dec 2025)	Change
Net Sales	Rs 84.00 crore	Rs 138.59 crore	+64.99%
Net Profit	Rs 1.17 crore	Rs 15.98 crore	+1472.02%
EBITDA	Rs 5.68 crore	Rs 28.36 crore	+399.3%
EPS	Rs 0.50	Rs 6.84	Higher YoY

ICICI Securities highlighted that Tatva Chintan Pharma Chem is guiding for an extended growth phase across FY26 and FY27. The brokerage noted that the company is aiming for 20-30% compound annual revenue growth over these two financial years, supported by existing facilities and a pipeline of products across segments including agro-chemicals, pharma intermediates and new applications.

"TATVA believes revenue growth of 20-30% p.a. is achievable for FY26/27, and current facility could support revenue of INR 8.5-9bn in three years. EBITDA margin is expected to stabilise in the range of 20-22%. Company anticipates acceleration in revenue to be visible in CY26, with supplies beginning for a large agro-chemical product and its photo-chlorination product; build-up is likely in CY27 with ramp-up of pharma intermediate," said the research analysts of ICICI Securities.

Tatva Chintan Pharma Chem segment trends, SDA, PASC and new products

"Tatva Chintan Pharma Chem's (TATVA) Q3FY26 print showed further signs of recovery, particularly in two key segments - SDA and PASC. Revenue in SDA grew 132% YoY driven by volumes while prices were stable. TATVA expects SDA revenue growth to sustain, with new customers' offtake in CY26 and likely demand for Euro-7 norms. PASC is likely to benefit from the commencement of supplies of two large agro-intermediates, with modest volumes, which could scale up in next two years," commented the research analysts of ICICI Securities.

The brokerage expects further progress on the pharma intermediate portfolio of Tatva Chintan Pharma Chem, along with contributions from electrolyte salts and agro-intermediates. "Pharma intermediate is on course for commercialisation in H2FY27. Electrolyte salts' orders for existing products have become frequent, with ramp-up in revenue likely in FY27. New agro-intermediate for domestic import substitution has been approved by customers, and may be an anchor for Jolva expansion. We cut FY26-27E EBITDA by 2-3% but raise TP to INR 1,955 (from INR 1,710) with an unchanged P/E multiple of 40x as we roll over valuation to FY28E. Retain BUY," they further recommended.

Tatva Chintan Pharma Chem electrolyte salts, semiconductor plans and CY28 product

The analysts also flagged emerging contributions from newer areas such as electrolyte salts and semiconductor-related products for Tatva Chintan Pharma Chem. These are expected to support diversification of the revenue mix, while also offering scope for higher value addition once volumes scale and commercial contracts deepen over the medium term.

"TATVA anticipates electrolyte salt contribution to rise in FY27 to 7-8% of total revenue. In semi-conductor, TATVA has received its first plant scale production order from a customer and batch production is expected to start in Feb'26. It has another product in pilot stage. The new product produced by TATVA could replace an established product which has higher toxicity; it is likely to start the commercial production in CY28, they further added.

Tatva Chintan Pharma Chem shareholding and Mukul Agrawal’s investment

Among notable investors in Tatva Chintan Pharma Chem, market participant Mukul Agrawal holds a meaningful stake as of Q3FY26. At the end of the December 2025 quarter, Agrawal owned 5,00,000 equity shares, representing a 2.14% holding in the company. Based on the current market price of about Rs 1,147, this stake is valued at roughly Rs 57.38 crore.

Agrawal first disclosed a position in Tatva Chintan Pharma Chem in July 2024, when the holding stood at 3,00,000 shares or 1.28% of equity. The stake was subsequently increased by 2,00,000 shares by the end of December 2025, taking the overall shareholding to 2.14%. The rising exposure suggests sustained interest in the company’s medium-term growth story.

Overall, Tatva Chintan Pharma Chem is reporting stronger quarterly numbers, a visible rebound in core segments such as SDA and PASC, and clearer guidance on future capacity utilisation. ICICI Securities’ projections of 20-30% annual revenue growth, margin stabilisation and new product launches in agro-chemicals, pharma intermediates, electrolyte salts and semiconductor applications are central to its valuation view and positive rating on the stock.